{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Is Annexon, Inc. technically bullish or bearish?
As of May 16, 2025, the trend is mildly bearish due to daily moving averages and monthly MACD indicating bearish momentum, despite some short-term strength from weekly indicators.
Who are in the management team of Annexon, Inc.?
As of March 2022, Annexon, Inc.'s management team includes CEO Douglas Love and Independent Chairman William Young, along with several independent directors: Jung Choi, Emmett Cunningham, Carol Gallagher, and Muneer Satter.
What does Annexon, Inc. do?
Annexon, Inc. is a clinical-stage biopharmaceutical company developing therapies for classical complement-mediated disorders, with a market cap of approximately $256.73 million and a recent net profit of -$54 million. The company operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap entity.
How big is Annexon, Inc.?
As of Jun 18, Annexon, Inc. has a market capitalization of 256.73 million and reported net sales of 0.00 million with a net profit of -167.38 million over the last four quarters. Shareholder's funds were valued at 293.11 million, and total assets amounted to 350.07 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
